PROCEPT BioRobotics (PRCT) 2024 Wells Fargo Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
2024 Wells Fargo Healthcare Conference summary
22 Jan, 2026HYDROS system launch and features
HYDROS, the next-generation robotic system, introduces AI Assist for assisted planning, improving surgical outcomes by reducing variability in treatment planning.
Workflow is streamlined, making setup easier and reducing reliance on specialist staff, addressing prior inefficiencies.
Enhanced imaging with improved ultrasound and a digital cystoscope simplifies the physician experience.
HYDROS is designed for mass market adoption, making it more accessible and appealing to a broader range of hospitals and surgeons.
The system is expected to accelerate patient flow and increase surgeon adoption within hospitals.
Commercial strategy and financial outlook
Initial HYDROS commercialization focuses on greenfield opportunities, with reps not incentivized to sell replacements in Q3 and Q4.
Average selling price (ASP) for HYDROS is guided at $380,000 for the back half of the year, with potential upside in 2025.
Margins are expected to remain stable, as HYDROS costs are comparable to AquaBeam, and higher ASPs are anticipated.
ROI for hospitals is expected to remain attractive, with potential for increased throughput and multisystem orders.
Some sales disruption is expected in Q3 due to rep training, but the transition should be complete by the end of 2024.
Market expansion and adoption
Near-term strategy remains focused on cannibalizing TURP and GreenLight procedures, with only 10% market share in resective surgery as of 2024.
HYDROS is expected to make the system more appealing to low and medium-volume hospitals, expanding the addressable market.
The company is piloting entry into the ASC setting, aiming for market expansion rather than shifting existing hospital procedures.
Same-day discharge rates are increasing, with 20-30% of patients discharged the same day, and some surgeons achieving over 90%.
Utilization growth is a key focus, with significant room to increase procedures per system and expand within existing accounts.
Latest events from PROCEPT BioRobotics
- Launch teams, inventory optimization, and HYDROS upgrades set the stage for growth in 2024–2026.PRCT
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Strong growth, margin expansion, and innovation drive leadership in BPH and new cancer markets.PRCT
Investor Day 202626 Feb 2026 - Q4 saw record procedures and 12% revenue growth, with 2026 guidance targeting 27%–33% growth.PRCT
Q4 202526 Feb 2026 - Improved visibility, rising utilization, and new clinical studies drive strong growth and margin expansion.PRCT
2024 Truist Securities MedTech Conference3 Feb 2026 - Q2 revenue up 61% to $53.4M, gross margin at 59%, FY24 guidance raised to $217M.PRCT
Q2 20242 Feb 2026 - FDA clears next-gen AI robotic system, reaffirming 2024 guidance and enabling broad US rollout.PRCT
Status Update1 Feb 2026 - Strong clinical results and expanding adoption drive growth, with new cancer studies underway.PRCT
The 44th Annual William Blair Growth Stock Conference31 Jan 2026 - Q3 revenue up 66% year-over-year, record gross margin, HYDROS launch, and strong cash position.PRCT
Q3 202418 Jan 2026 - HYDROS launch accelerates sales, boosts margins, and expands clinical and market opportunities.PRCT
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026